AlphaQuest LLC Sells 940 Shares of LeMaitre Vascular, Inc. $LMAT

AlphaQuest LLC lessened its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 11.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,563 shares of the medical instruments supplier’s stock after selling 940 shares during the quarter. AlphaQuest LLC’s holdings in LeMaitre Vascular were worth $628,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Congress Asset Management Co. raised its position in LeMaitre Vascular by 4.6% during the second quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after acquiring an additional 29,553 shares in the last quarter. Northern Trust Corp raised its position in shares of LeMaitre Vascular by 5.4% in the first quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock valued at $28,993,000 after purchasing an additional 17,748 shares during the period. Envestnet Asset Management Inc. raised its position in shares of LeMaitre Vascular by 9.9% in the first quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier’s stock valued at $23,921,000 after purchasing an additional 25,680 shares during the period. Russell Investments Group Ltd. raised its position in shares of LeMaitre Vascular by 11.6% in the first quarter. Russell Investments Group Ltd. now owns 264,261 shares of the medical instruments supplier’s stock valued at $22,172,000 after purchasing an additional 27,470 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after purchasing an additional 55,804 shares during the period. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total transaction of $999,197.85. Following the completion of the sale, the director owned 17,976 shares in the company, valued at $1,660,802.64. This represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 120,815 shares of company stock worth $11,280,206. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Trading Up 1.0%

Shares of LMAT stock opened at $90.12 on Tuesday. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The firm’s fifty day simple moving average is $91.21 and its 200 day simple moving average is $86.84. The firm has a market capitalization of $2.04 billion, a P/E ratio of 43.75, a price-to-earnings-growth ratio of 2.30 and a beta of 0.77. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. LeMaitre Vascular’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular’s payout ratio is 38.83%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Wednesday, October 8th. Finally, Barrington Research reissued an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $97.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.